Another nonconcordant study, the study of Furusyo et al. 2012, used raloxifene hydrochloride (RLX) (oral selective estrogen receptor modulator) plus SOC (standard of care) treatment in postmenopausal women with genotype 1b chronic hepatitis C; the SVR rate was significantly higher for RLX plus SOC patients (61.3%) than for SOC only patients (34.4%) (P = 0.0051) [34]. The gene discussed is ESR1; the disease is chronic hepatitis C virus infection.